Product News
Filter News
Found 274,553 articles
-
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
4/24/2024
Gain Therapeutics, Inc. announces positive results from the single ascending dose (SAD) part of its Phase 1 study.
-
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
4/24/2024
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.
-
Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer
4/24/2024
Naveris, Inc. today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer.
-
n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients
4/24/2024
n-Lorem, a nonprofit foundation , announced a new partnership with Hongene Biotech Corporation that supports n-Lorem’s efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.
-
Blue Arbor Technologies Receives FDA Breakthrough Device Designation and TAP Enrollment for the RESTORE™ Neuromuscular Interface System
4/24/2024
Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.
-
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
4/24/2024
Renovaro Inc. and Cyclomics proudly announce a significant milestone in their collaboration.
-
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
4/24/2024
Helius Medical Technologies, Inc. today announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device.
-
GenEmbryomics and Progenesis Announce Strategic Partnership to Transform IVF Testing
4/24/2024
In a move that is set to transform clinical reproductive medicine, GenEmbryomics Limited and Progenesis Inc, today announced a groundbreaking collaboration to enhance access to cutting-edge reproductive technologies.
-
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
4/24/2024
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership at the European Society of Clinical Microbiology and Infectious Disease Global Congress taking place April 27-30, 2024, in Barcelona, Spain.
-
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
4/24/2024
scPharmaceuticals Inc. today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.
-
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
4/24/2024
Pasithea Therapeutics Corp. today announced the first cohort of 3 patients have commenced dosing. PAS-004 is being evaluated in a Phase 1 multicenter open label clinical trial (NCT06299839 ) in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.
-
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
4/24/2024
Immutep Limited today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.
-
Moderna and OpenAI Collaborate To Advance mRNA Medicine
4/24/2024
Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare.
-
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
4/24/2024
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples.
-
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
4/24/2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.
-
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
4/24/2024
First Wave BioPharma, Inc. announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special issue "Recent Advances in Gluten-Free Diet and Celiac Disease" in the peer-reviewed scientific journal, Nutrients.
-
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
4/24/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the second and final tranche of its private placement financing of Units for $3.8 million representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024.
-
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
4/24/2024
Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target
4/24/2024
GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
-
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad
4/24/2024
Spago Nanomedical AB announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer.